GLSI
NASDAQGreenwich LifeSciences Inc.
Price$18.45-8.55 (-31.69%)
2026-05-212026-08-25
News · 26 weeks25-71%
2026-03-012026-08-23
Mix1290d
- Offering7(58%)
- Insider3(25%)
- SEC Filings2(17%)
Latest news
25 items- SECSEC Form 10-Q filed by Greenwich LifeSciences Inc.10-Q - Greenwich LifeSciences, Inc. (0001799788) (Filer)
- PRGreenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027STAFFORD, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to January 31, 2027 which is approximately 76 months from the date of the Company's IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common s
- INSIDERCEO and CFO Patel Snehal bought $29,555 worth of shares (2,200 units at $13.43), increasing direct ownership by 0.04% to 5,611,402 units (SEC Form 4)4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
- INSIDERCEO and CFO Patel Snehal bought $20,430 worth of shares (1,500 units at $13.62), increasing direct ownership by 0.03% to 5,609,202 units (SEC Form 4)4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
- INSIDERCEO and CFO Patel Snehal bought $47,018 worth of shares (3,600 units at $13.06), increasing direct ownership by 0.06% to 5,607,702 units (SEC Form 4)4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
- PRGreenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United KingdomSTAFFORD, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the regulatory approval to expand FLAMINGO-01 into the United Kingdom. The Company's application to expand FLAMINGO-01 into the UK has been formally approved by UK regulators, thus adding potentially 5-10 geographically distributed UK sites to the approximately 170-180 approved sites in the US and Europe. The Company is collaborating with The Royal Marsden, a leading cancer research i
- PRGreenwich LifeSciences Provides Clinical Updates on FLAMINGO-01STAFFORD, Texas, July 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following clinical updates on FLAMINGO-01. FLAMINGO-01 Data Safety Monitoring Board (DSMB) The FLAMINGO-01 DSMB met in May 2026 and recommended the study continue as is without modification. FLAMINGO-01 Steering Committee Clinical Strategy On December 22, 2025, the company announced the following objectives: "The Steering Committee also met at SABCS 2025 and discussed the clini
- PRGreenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01STAFFORD, Texas, July 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the combination of both HLA-A*02 and non-HLA-A*02 patients in FLAMINGO-01 in Europe. All European and US Sites to Combine All Patients Independent of HLA Type in the Randomized Arms of FLAMINGO-01 The Company previously announced that US clinical sites started enrolling both HLA-A*02 and non-HLA-A*02 patients in the same randomized arms in FLAMINGO-01, based on
- PRGreenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01STAFFORD, Texas, July 09, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the use of commercially manufactured GP2 in FLAMINGO-01 in Europe. All European and US Sites to Treat Patients with Commercially Manufactured GP2 The Company previously announced that the first three commercial lots of GP2 active ingredient were manufactured in 2023 in an approved commercial facility, which could be used to prepare approximately 200,000 doses of
- SECSEC Form 10-K filed by Greenwich LifeSciences Inc.10-K - Greenwich LifeSciences, Inc. (0001799788) (Filer)
- PRGreenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today presents the published abstract and poster from the ASCO Annual Meeting 2026. The abstract is shown below and the poster being presented today can be seen and downloaded at the bottom of the Phase III clinical trial tab on the Company's website here. This is the second abstract and poster presented jointly with the Steering Committee of FLAMINGO-01 with statistically signi
- PRGreenwich LifeSciences Provides Update Regarding Form 10-K FilingSTAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025. The Form 10-K for the fiscal year ending December 31, 2025, continues to be audited by our new auditor and we believe it is in the final approval steps. The Form 10-K also includes the 2024 audit that was previously audited by the prior auditor. As previously indicated, the accounts pay
- PRGreenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q FilingSTAFFORD, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that on May 20, 2026, the Company received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, because it has not yet filed its Quarterly Report on Form 10-Q for the three months ended March 31, 2026, the Company is not currently in compliance with Nasdaq Listing Rule 5250(c)(1), which req
- PRGreenwich LifeSciences Provides Update Regarding Form 10-K FilingSTAFFORD, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025. The Form 10-K for the fiscal year ending December 31, 2025 is still being audited by the auditors who are both trying to reach agreement on the final figures. They have indicated that they expect to complete their audits before the end of May in conjunction with the filing of Form 10-Q
- PRGreenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026STAFFORD, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that an abstract has been accepted for publication at the upcoming 2026 ASCO Annual Meeting along with a corresponding poster presentation. The 2026 ASCO Annual Meeting will be held from May 28 to June 2, 2026. The full text of the abstract and poster will be available on June 1, 2026, the day of the presentation. CEO Snehal Patel commented, " We look forward to
- PRGreenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K FilingSTAFFORD, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that on April 16, 2026, the Company received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, because it has not yet filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, the Company is not currently in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely
- PRGreenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026STAFFORD, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today presents the published abstract and poster from the AACR Meeting 2026. The abstract is shown below and the poster being presented today can be seen and downloaded at the bottom of Phase III clinical trial tab on the Company's website here. This is the first abstract and poster presented jointly with the Steering Committee of FLAMINGO-01 with statistically significant dela
- PRGreenwich LifeSciences Provides Update on Financing StrategySTAFFORD, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided additional updates on its financing strategy. The Company's ATM financing vehicle allows the Company to sell its common stock directly into the trading market at market price. The amount raised through our ATM for Q1 2026 exceeded the Company's Q1 2026 cash burn rate, leading to a Q1 2026 cash balance of approximately $10.5 million as of March 31, 2026. The above
- PRGreenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market PotentialSTAFFORD, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on new patent claims based on FLAMINGO-01 statistically significant open label immune response and recurrence rate data. Statistically significant immune response and recurrence rate data is the basis for new claims recently filed that GLSI-100 clinically benefits non-HLA-A*02 patients, which the Company believes increases the market for GLSI-100 by an a
- SECSEC Form NT 10-K filed by Greenwich LifeSciences Inc.NT 10-K - Greenwich LifeSciences, Inc. (0001799788) (Filer)
- PRGreenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01STAFFORD, Texas, March 19, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of new clinical sites in the US. The Phase III clinical trial has recently been activated at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States – specifically at its network sites in Los Angeles and Orange counties, Arizona, Atlanta, and Illinois. Principal investigator at City of Hop
- PRGreenwich LifeSciences Provides Update on Upcoming AACR MeetingSTAFFORD, Texas, March 18, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on the upcoming AACR Meeting 2026. Two abstracts and two posters were accepted for presentation. The titles and authors of the abstracts are as follows: Abstract Number: CT138 - Poster Section 52 on April 20, 2026, 2-5pm Abstract Title: Preliminary delayed-type-hypersensitivity immune response results from open-label arm of on-going Phase III study to
- PRGreenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01STAFFORD, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided a preliminary update showing a continued reduction in the recurrence rate in the fully enrolled, 250 patient, open label non-HLA-A*02 arm of FLAMINGO-01. 6 Months of Additional Patient Data Since Last Update Shows Recurrence Rate of <1% per Year in Non-HLA-A*02 Patients Treated with GLSI-100, Following Completion of Primary Immunization Series (PIS)This <1% Annual Recurrence Rate Obser
- PRGreenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01STAFFORD, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the use of commercially manufactured GP2 in FLAMINGO-01. All US Sites Treating Patients with Commercially Manufactured GP2 The Company previously announced that the first three commercial lots of GP2 active ingredient were manufactured in 2023 in an approved commercial facility, which could be used to prepare approximately 200,000 doses of GP2. In 2024, the fir
- PRGreenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01STAFFORD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on the increased patient screen rate in FLAMINGO-01. FLAMINGO-01 Annual Patient Screen Rate Increases to Over 800 Patients per Year Over the past 6 months, the Company achieved its highest screening rate of approximately 200 patients per quarter or the equivalent of over 800 patients per year in the US and EU sites, which is an approximately 33% increas
GLSI FAQ
7 questionsWhat does Greenwich LifeSciences Inc. do?
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Where does GLSI stock trade?
Greenwich LifeSciences Inc. (GLSI) is listed on NASDAQ.What sector and industry is GLSI in?
Greenwich LifeSciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Greenwich LifeSciences Inc. go public?
Greenwich LifeSciences Inc. (GLSI) completed its IPO in 2020.What are analysts saying about GLSI?
Greenwich LifeSciences Inc. has had 2 recent analyst actions on file. The most recent action was from Noble Capital Markets: Outperform with a $4500.00 price target on 2025-08-20. Recent price targets cluster around $4500.00.What companies are similar to GLSI?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare GLSI side-by-side with any of them on Quantisnow.How can I track GLSI on Quantisnow?
Quantisnow aggregates Greenwich LifeSciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GLSI to receive live email and push alerts on every new disclosure.